Thanks for starting the very educative portfolio-restructuring thread. I am posting for the first time in this thread. I built a portfolio with objective similar to the headline of the thread. I think the stocks in the portfolio can be good discussion point in terms of their growth prospects. The stocks are
1 Advanced Enzyme market cap Rs.4622.49 crore (weight 30%)
2 Alphageo market cap Rs.592.40 crore (Weight 15%)
3 Caplin point labs market cap Rs.2657.85 crore (Weight 5%)
4 Infibeam market cap Rs.5885.85 crore (weight 10%)
5 Intense technologies market cap Rs.328.59 crore (Weight 10%)
6 Intrasoft market cap Rs.651.80 crore (Weight 6%)
7 Moldtek packaging market cap Rs.531.11 crore (Weight 2%)
8 Rishi techtex market cap Rs.20.52 crore (Weight 2%)
9 Strides Shasun market cap Rs.9826.09 crore (Weight 10%)
10 Tasty bite market cap Rs.923.76 crore (weight 10%)
TOTAL MARKET CAP Rs.26,040.46 crore
I hope each of these scrips have potential for more than 25% growth for the next 4-5 years.
The portfolio is selected keeping in view the vast addressable market, durable moat, simplicity of businesses etc. The ideas/analysis/criticism of each of these companies or any other company that deserve a place here are welcome.
The market cap of each company in the model portfolio is indicated so that the performance can be measured at any given time, ideally every quarter. The performance is proposed to be measured individual company wise and the total market cap of the portfolio. I have also assigned weightage to each company based on my conviction on the stock. The idea is Few bets, Big bets and infrequent bets. The weight can be assigned to any size of portfolio like 1 lakh to 10 lakh or 20 lakhs to arrive at the quantity of stocks. Portfolio composition and the weightage to individual companies is not rigid and is open for discussion in the forum.
Market is full of opportunities and portfolio is flexible to accommodate better and exciting ideas/opportunities. It is proposed to accommodate maximum of 12 stocks to keep the portfolio manageable. Existing stocks can be replaced with new ones based on the performance of the stocks if they fail to meet the expectation.
The model portfolio idea is for learning purpose only and should not be construed as recommendation to invest.
Please do your due diligence before taking investment decision.
Disclosure: I have investments in all the above shares and my views may be biased
I am also a new user.
I am holding caplin point laboratories in my portfolio and pretty much confident of 25 percent growth for next 4 to 5 years because this company is entirely different in compared with other companies. They are entering USA market which is more lucrative market.
One more point I like to discuss that “they are focussing on IV formulations” .
Claris life sciences sold 75 percent of IV formulations to Baxter at 4500 cr. So there is a great scope for rerating of stock.
If you see market cap of claris is just 1900 cr . Less than caplin point laboratories then you can imagine that caplin point laboratories can be sold at what price.
Moat : they have created a biggest distribution channel in Latin America this is very difficult to create by any company in next 4 to 5 years.
Please use this thread for ideation purposes. (but make the effort to go beyond just naming candidates that you hope/think/know passes the growth test - there’s more to it thatn just growth, right?)
Ideally we are supposed to slot in prospective candidates in a certain category along the lines of categories suggested - because the aim is not to stock-pick, but to be able to construct a all-weather portfolio that fares better in different market conditions/cycles in play. Which means some segments of portfolio are there to provide stability, at any point of time/cycle - there would be 2-3 segments that will hold off well, and the like.
Please maintain that discipline, so that this doesn’t become another direction-less thread. Lets hold ourselves accountable to the objective of the thread.Those of us who try and take the trouble of some thinking-through and edit our posts, suitably, we will be richer for that attempt, I can guarantee that.
Caplin - One has to play on their niche marking strategy instead of USA branded drug income (which might be after 2019). Even they get FDA approval of the site, they will do Contract Manufacturing for other company in a way of site-transfer. However, their focus on improving marking strategy (sourcing cheap from China and selling higher price in small country where big player is not interested) is the real growth driver in near future.
Alphageo - Revenues might fluctuates on government policy on exploration. Stock price already run ahead of growth…mean reversal is possible!. Good point - capital light structure and profit margin might improve further in future. Niche in seismic data analysis
For any long term investor, looking at an investment from 5-7 year perspective, this would be valid if
those niches have a big opportunity in decent market size (> 25000 cr) or part of rapidly growing (>15% CAGR) market.
If a company is operating in a niche business with current revenue of 500 cr where total potential revenue can only be 3-5k cr, then you can roughly imagine what max market cap the company can get to.
Just operating in a niche business is no guarantee of big riches. Would be good if you can explain the opportunity/market size of some of these companies as well.
The information on market size for Advanced Enzyme Tech presented above is too technical. The following data may help in understanding the market:
Based on the type of end-user industries, the global enzyme industry can be categorised into two segments-industrial and specialty enzymes. The industrial enzymes segment includes enzymes which cater to F&B, detergents, bio-fuel, animal feed, textile and other industries;the specialty enzymes segment consists of products which cater to pharmaceuticals, research and biotechnology, diagnostics and biocatalysts. Both the industrial and specialty enzymes segments are expected to grow over the next few years. Global enzyme demand is forecast to grow at a CAGR of 6.9% to $11.3 bn from $5.8 bn over 2010-20. Specialty enzymes are likely to witness a CAGR of 7.5%, higher than the forecast of 6.5% CAGR for industrial enzymes. Growth in the specialty enzymes segment is likely to be driven by diagnostic and research and biotechnology enzymes,which in turn will be fuelled by an increase in the number of people gaining access to medical facilities in developing nations and healthcare reforms in the US. Demand for industrial enzymes is expected to be bolstered by the animal feed segment and the F&B segment.
Currently, the Indian enzymes industry is at a nascent stage and penetration across end-user industries is low. Several factors such as price-sensitivity and lack of awareness among end-user industries, and the government’s failure to strictly implement environmental laws have impeded the industry from fully realising its growth potentials.At present, there are approximately 17 players in the Indian enzyme market. Most of these companies focus on producing value-added enzyme products based on simpler formulations. However, the entry of foreign manufacturers has led to availability of quality products in the domestic market, which provides clients with a choice of more innovative solutions. The domestic industry is increasingly eyeing the international markets -most of the enzyme products manufactured in the country are exported, and some of the major players are establishing base in foreign markets. Pharmaceuticals, textile, detergent, F&B, and leather and paper industries are the primary consumers of enzyme products in India. Each segment is at a different stage of growth. The pharmaceutical segment is at a nascent stage. Leather and textile processing segments are relatively mature, whereas the detergent segment is growing. The bio-Industrial (primarily enzyme products) market in India was worth ₹7.7 bn in 2013. The industry has registered 15.1% CAGR over 2004-13. The industry is expected to continue to grow to $295 mn in 2020 from $96 mn in 2010at a CAGR of 12%.
F&B segment is expected to drive growth for industrial enzymes Enzymes used in F&B processing currently account for the largest share (over 20%) of the overall demand for industrial enzymes. Along with animal feed, the F&B segment is likely todrive the demand for industrial enzymes in the coming years. With a CAGR of 8.4% over 2010-20, the animal feed segment is estimated to be the fastest growing among all segments within the enzymes industry, followed by the F&B segment which is expected to grow at a CAGR of 7.5% over 2010-2020.The F&B industry is estimated to grow to $2.7 trillion by 2020 from $1.8 trillion in 2010at a 4.1% CAGR over the period.Developing countries are expected to drive this growth. Increasing disposable income and rising living standards in these nations are leading to greater per capita F&B consumption, and increasing demand for high quality processed foods. In developed nations, increased consumption of ready-to-eat products and organic foods is expected to propel growth. Enzymes have a variety of applications across dairy, starch processing, baking, malting and other industries within the F&B segment. With the growth in F&B consumption, increasing emphasis on food quality and demand for organic foods, the need for enzymes from this segment is expected to grow significantly.
In India, robust economic growth, expansion in middle class population and increase in health awareness have led to demand for high quality food. This has fuelled growth of the food processing industry, which is forecast to grow at a CAGR of 5.8% over 2007-15. With expanding growth,the industry is likely to become more organised, which is expected to contribute to steady demand for enzyme products.
The information is sourced from a research report by CRISIL and is posted only for understanding the market potential of enzymes and is not to be construed as recommendation to invest.
Please refer to the original post which is revised.
Yes Bank plans to raise Rs.10000 crore through various private placement options. The bank seems to be on the right track to deliver excellent results going forward.
Multi Commodity Exchange of India will soon introduce Options trading. Some HNI has bought a Rs.300 crore stake via preferential allotment. With ‘dabba’ trading coming to a halt, there exists a big opportunity for this company. Its share price could double in two years.
Intellect Design Arena has recently given a growth guidance of 16-22% for the next few years. The stock is available at attractive levels and could double in two years.
The demonetization along with GST is going to squeeze out the informal sector. Effected parties include APPARELs, TRANSPORT, Real Estate, Small Jewellers, PVT. Educational societies etc in a big way. Even it will impact informal lenders also.
The black marketeers will devise new ways again to do same. The new govt. may withdraw new 2000/- and 500/- as lot of cashless ways of transactions are already in place. If UPI of NPCI is successful, the govt this time may demonetize with extra ease.
The survivors will be those who will formalize their business. The industry (efficient) leaders who face tough competition from informal sector stand to gain the most.
Will they be from Plywood, Apparels, Logistics, Real estate, Jewelers, Tyre Re-treaders or MFI/SFB ?
It is better if we can throw some light on them.
Can you explain how DeMo (and GST) squeeze the informal sector ? Just want to know your though process. Assuming hardly any black money is recovered after DeMo, I don’t see how small jewelers lose out. They will again start doing the same black cash transactions. On the other hand, the organized jewelry will feel the heat if the transaction size is more than 2L.
@nagesh_reddy the list is mostly a value play. most of us in this forum focus mostly on businesses which are on the cusp of high growth or are growing rapidly. but decent, established and somewhat boring businesses with consistent performance year after year can contain huge value when underpriced. And exaggerated underpricing do happen time to time when markets fall or some quarter numbers are bad.
The list assumes - a non-commodity business with zero to moderate leverage - with consistent return on equity over the years will most likely have similar returns in the next 3-5 years atleast. (Unless their industry is under disruption or there is black swan that we are not aware of).
Now, knowing the approximate return on equity capital in the coming few years, it’s easy to calculate the intrinsic price. For e.g a business with an average roe of 15% over the years…we can expect it to deliver a compounded return on equity of at least 12% over the next few years. A business which returns 12% can be expected to trade at a price to book of about 2.75. so if it is trading at say 1.5 p/b …we can safely assume it is underpriced and expect the price to correct on the upside in the next 3-4 years. In the above scenario, the price of this security after three years would be around 2.75×1.09^3 = 3.56 (using 9% as the discount rate in the DCF model). with a current price of 1.5, the return expected is 3.56/1.5= 2.3x …so a 2 to 2.5 bagger in the next 3-4 years. This assumes 12% roe. Anything more would be a bonus surprise.
There is no particular reason for not having Financial sector stocks.
Basanth Maheshwari in his book ‘The Thoughtful Investor’ says that there are many stocks in the market that give 15% return but 20% and above return is rare. The compounding effect of high growers over longer periods is a clear advantage. I was concentrating more on > 20% growers, which are in small to mid cap category that are leaders in their category and are growing revenues at a fast clip and which are not widely recognized. At the same time I wanted to restrict the stocks to 10.
I like to have Capital First, Indiabulls Housing, CARE and MCX from the sector in the portfolio but not willing to let go the existing stocks. I consider the existing stocks are secular growth stories and are likely to expand EPS and PE multiples for a long period.
Of course nothing can be taken for granted, the performance is to be monitored periodically. If a compelling opportunity in financial sector comes along, it would be included by replacing the under performers in the portfolio.
Looking for an exciting stock from the sector.